Lanosterol
CAS 79-63-0
Lanosterol (CAS 79-63-0) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Kd | 624 nM | 2 | - |
| - | EC50 | 1420 nM | 1 | - |
| - | Potency | 12589.3 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Farnesoid X receptor-β Nr1h5 |
Agonist | 6.0 pEC50 | 12529392 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Lanosterol used for in pharmaceutical contexts?
Lanosterol (CAS 79-63-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Lanosterol?
No adverse-event association or SIDER side-effect rows are rendered for Lanosterol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Lanosterol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Lanosterol with EU status "permitted".
What clinical phase is Lanosterol in?
No phase 1-4 clinical development badge is rendered for Lanosterol because the matched compound identifier rows do not contain a max-phase value.